These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

188 related articles for article (PubMed ID: 25976187)

  • 1. Aceruloplasminaemia: a rare but important cause of iron overload.
    Doyle A; Rusli F; Bhathal P
    BMJ Case Rep; 2015 May; 2015():. PubMed ID: 25976187
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Aceruloplasminaemia with progressive atrophy without brain iron overload: treatment with oral chelation.
    Skidmore FM; Drago V; Foster P; Schmalfuss IM; Heilman KM; Streiff RR
    J Neurol Neurosurg Psychiatry; 2008 Apr; 79(4):467-70. PubMed ID: 17911185
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Aceruloplasminaemia: a disorder of diabetes and neurodegeneration.
    Calder GL; Lee MH; Sachithanandan N; Bell S; Zeimer H; MacIsaac RJ
    Intern Med J; 2017 Jan; 47(1):115-118. PubMed ID: 28076908
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Aceruloplasminaemia: a family with a novel mutation and long-term therapy with deferasirox.
    Lindner U; Schuppan D; Schleithoff L; Habeck JO; Grodde T; Kirchhof K; Stoelzel U
    Horm Metab Res; 2015 Apr; 47(4):303-8. PubMed ID: 25089372
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Iron chelation therapy to prevent the manifestations of aceruloplasminemia.
    Bove F; Fasano A
    Neurology; 2015 Sep; 85(12):1085-6. PubMed ID: 26311749
    [No Abstract]   [Full Text] [Related]  

  • 6. Combination-therapy with concurrent deferoxamine and deferiprone is effective in treating resistant cardiac iron-loading in aceruloplasminaemia.
    Badat M; Kaya B; Telfer P
    Br J Haematol; 2015 Nov; 171(3):430-2. PubMed ID: 25855051
    [No Abstract]   [Full Text] [Related]  

  • 7. Central nervous system involvement in a rare genetic iron overload disorder.
    Bethlehem C; van Harten B; Hoogendoorn M
    Neth J Med; 2010 Oct; 68(10):316-8. PubMed ID: 21071777
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Iron chelation therapy in myelodysplastic syndrome - Cui bono?
    Tefferi A; Stone RM
    Leukemia; 2009 Aug; 23(8):1373. PubMed ID: 19672273
    [No Abstract]   [Full Text] [Related]  

  • 9. Deferasirox administration for the treatment of non-transfusional iron overload in patients with thalassaemia intermedia.
    Ladis V; Berdousi H; Gotsis E; Kattamis A
    Br J Haematol; 2010 Dec; 151(5):504-8. PubMed ID: 20950401
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Clinical monitoring and management of complications related to chelation therapy in patients with β-thalassemia.
    Saliba AN; El Rassi F; Taher AT
    Expert Rev Hematol; 2016; 9(2):151-68. PubMed ID: 26613264
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Novel ceruloplasmin mutation causing aceruloplasminemia with hepatic iron overload and diabetes without neurological symptoms.
    Rusticeanu M; Zimmer V; Schleithoff L; Wonney K; Viera J; Zimmer A; Hübschen U; Bohle RM; Grünhage F; Lammert F
    Clin Genet; 2014 Mar; 85(3):300-1. PubMed ID: 23557349
    [No Abstract]   [Full Text] [Related]  

  • 12. Iron overload in thalassemia and related conditions: therapeutic goals and assessment of response to chelation therapies.
    Porter JB; Shah FT
    Hematol Oncol Clin North Am; 2010 Dec; 24(6):1109-30. PubMed ID: 21075283
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Results from a 1-year, open-label, single arm, multi-center trial evaluating the efficacy and safety of oral Deferasirox in patients diagnosed with low and int-1 risk myelodysplastic syndrome (MDS) and transfusion-dependent iron overload.
    Nolte F; Höchsmann B; Giagounidis A; Lübbert M; Platzbecker U; Haase D; Lück A; Gattermann N; Taupitz M; Baier M; Leismann O; Junkes A; Schumann C; Hofmann WK; Schrezenmeier H
    Ann Hematol; 2013 Jan; 92(2):191-8. PubMed ID: 23073603
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Uses and limitations of serum ferritin, magnetic resonance imaging T2 and T2* in the diagnosis of iron overload and in the ferrikinetics of normalization of the iron stores in thalassemia using the International Committee on Chelation deferiprone/deferoxamine combination protocol.
    Kolnagou A; Yazman D; Economides C; Eracleous E; Kontoghiorghes GJ
    Hemoglobin; 2009; 33(5):312-22. PubMed ID: 19814677
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Diagnosing aceruloplasminemia: navigating through red herrings.
    Kharel Z; Kharel H; Phatak PD
    Ann Hematol; 2024 Jun; 103(6):2173-2176. PubMed ID: 38637332
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Hepatic but not brain iron is rapidly chelated by deferasirox in aceruloplasminemia due to a novel gene mutation.
    Finkenstedt A; Wolf E; Höfner E; Gasser BI; Bösch S; Bakry R; Creus M; Kremser C; Schocke M; Theurl M; Moser P; Schranz M; Bonn G; Poewe W; Vogel W; Janecke AR; Zoller H
    J Hepatol; 2010 Dec; 53(6):1101-7. PubMed ID: 20801540
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Efficacy of Deferasirox (Exjade®) in Modulation of Iron Overload in Patients with β-Thalassemia Intermedia.
    Karimi M; Arandi N; Haghpanah S; Ansari S; Azarkeyvan A; Bordbar M; Safaei S
    Hemoglobin; 2015; 39(5):327-9. PubMed ID: 26114738
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Iron chelation therapy in aceruloplasminaemia: study of a patient with a novel missense mutation.
    Mariani R; Arosio C; Pelucchi S; Grisoli M; Piga A; Trombini P; Piperno A
    Gut; 2004 May; 53(5):756-8. PubMed ID: 15082597
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Efficacy and safety of deferasirox in β-thalassemia major patients in Iran: a prospective study from a single referral center in Iran.
    Alavi S; Ebadi M; Ghazizadeh F; Arzanian MT; Shamsian B; Abdollah Gorji F
    Pediatr Hematol Oncol; 2014 Feb; 31(1):76-86. PubMed ID: 24383712
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Effectiveness of oral iron chelator treatment with deferasirox in an aceruloplasminemia patient with a novel ceruloplasmin gene mutation.
    Suzuki Y; Yoshida K; Aburakawa Y; Kuroda K; Kimura T; Terada T; Kono S; Miyajima H; Yahara O
    Intern Med; 2013; 52(13):1527-30. PubMed ID: 23812204
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.